Destiny Pharma has successfully raised £6.45m in a Placing, Subscription, and Open Offer which, apart from funding the further preparation of its two lead assets for the Phase 3 studies, puts Destiny in a stronger position in licensing negotiations.
Pfizer’s C.difficile toxin vaccine to prevent CDIs failed this primary endpoint in Phase 3. This shows that the prevention of not every infection is tractable by traditional vaccines. For novel and more difficult indications like CDIs, new approaches like a microbiome-directed approach are needed; but unfortunately for Destiny’s microbiome competitor Finch, safety concerns meant the FDA placed their Phase 3 study on clinical hold.
The fundraising, dilution and model changes have resulted in our valuation changing from £187.9m or 314p per share to £210.3m or 289p per share.
29 Mar 2022
NTCD-M3 competitors stumble while issue approved
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
NTCD-M3 competitors stumble while issue approved
Destiny Pharma Plc (DEST:LON) | 19.2 0.2 5.5% | Mkt Cap: 18.3m
- Published:
29 Mar 2022 -
Author:
Andy Smith -
Pages:
5
Destiny Pharma has successfully raised £6.45m in a Placing, Subscription, and Open Offer which, apart from funding the further preparation of its two lead assets for the Phase 3 studies, puts Destiny in a stronger position in licensing negotiations.
Pfizer’s C.difficile toxin vaccine to prevent CDIs failed this primary endpoint in Phase 3. This shows that the prevention of not every infection is tractable by traditional vaccines. For novel and more difficult indications like CDIs, new approaches like a microbiome-directed approach are needed; but unfortunately for Destiny’s microbiome competitor Finch, safety concerns meant the FDA placed their Phase 3 study on clinical hold.
The fundraising, dilution and model changes have resulted in our valuation changing from £187.9m or 314p per share to £210.3m or 289p per share.